Esbriet and Weight abnormal - a phase IV clinical study of FDA data

Summary:

Weight abnormal is reported as a side effect among people who take Esbriet (pirfenidone), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Seroquel, and have Idiopathic pulmonary fibrosis.

The phase IV clinical study analyzes which people have Weight abnormal when taking Esbriet. It is created by eHealthMe based on reports of 39,843 people who have side effects when taking Esbriet from the FDA, and is updated regularly.

What is Esbriet?

Esbriet has active ingredients of pirfenidone. eHealthMe is studying from 39,858 Esbriet users. Check the latest studies of Esbriet.

What is Weight abnormal?

Weight abnormal is found to be associated with 1,751 drugs and 1,285 conditions by eHealthMe. Check the latest studies of Weight abnormal.

On Dec, 21, 2025

39,843 people reported to have side effects when taking Esbriet.
Among them, 27 people (0.07%) have Weight abnormal.

Among these 27 people:

How long have people been on Esbriet when they have Weight abnormal? *

What is the gender of people who have Weight abnormal when taking Esbriet? *

female: 22.22 %
male: 77.78 %

What is the age of people who have Weight abnormal when taking Esbriet? *

What are other drugs people take besides Esbriet? *

What are other side effects people have besides Weight abnormal? *

Dyspnea (difficult or laboured breathing): 21 people, 77.78%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 18 people, 66.67%
Weight Decreased: 17 people, 62.96%
General Physical Health Deterioration (weak health status): 14 people, 51.85%
Weakness: 13 people, 48.15%
Fatigue (feeling of tiredness): 13 people, 48.15%
Diarrhea: 12 people, 44.44%
Ageusia (loss of taste functions of the tongue): 10 people, 37.04%
Nausea (feeling of having an urge to vomit): 10 people, 37.04%
Gastric Disorder (disease of stomach): 9 people, 33.33%

What are the existing conditions these people have? *

Idiopathic Pulmonary Fibrosis (chronic lung disease): 27 people, 100.00%
Interstitial Lung Disease: 2 people, 7.41%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 7.41%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 3.70%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 3.70%
Indigestion: 1 person, 3.70%
High Blood Cholesterol: 1 person, 3.70%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 3.70%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 3.70%
Cough: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Esbriet and have Weight abnormal?

- Check whether Weight abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Esbriet:

Esbriet (39,858 reports)

Weight abnormal treatments and more:

Weight abnormal (2,837 reports)

Browse all side effects of Esbriet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight abnormal:

Weight abnormal (1,751 drugs)

Browse all the conditions that are associated with Weight abnormal:

Weight abnormal (1,285 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pirfenidone (the active ingredients of Esbriet) and Esbriet (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.